SELLAS Life Sciences Group Inc (SLS)
1.215
+0.08
(+6.58%)
USD |
NASDAQ |
Jul 05, 15:46
SELLAS Life Sciences Group SG&A Expense (TTM): 14.29M for March 31, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 14.29M |
December 31, 2023 | 13.86M |
September 30, 2023 | 14.38M |
June 30, 2023 | 13.70M |
March 31, 2023 | 13.66M |
December 31, 2022 | 12.58M |
September 30, 2022 | 11.51M |
June 30, 2022 | 11.08M |
March 31, 2022 | 10.78M |
December 31, 2021 | 11.32M |
September 30, 2021 | 12.08M |
June 30, 2021 | 11.77M |
March 31, 2021 | 10.96M |
December 31, 2020 | 9.60M |
September 30, 2020 | 8.712M |
June 30, 2020 | 8.972M |
March 31, 2020 | 9.623M |
December 31, 2019 | 9.923M |
September 30, 2019 | 10.16M |
June 30, 2019 | 9.121M |
March 31, 2019 | 11.39M |
December 31, 2018 | 12.77M |
September 30, 2018 | 16.12M |
June 30, 2018 | 18.28M |
March 31, 2018 | 17.22M |
Date | Value |
---|---|
December 31, 2017 | 15.62M |
September 30, 2017 | 4.742M |
June 30, 2017 | 4.079M |
March 31, 2017 | 3.355M |
December 31, 2016 | 4.593M |
September 30, 2016 | 12.23M |
June 30, 2016 | 12.28M |
March 31, 2016 | 11.05M |
December 31, 2015 | 10.61M |
September 30, 2015 | 11.35M |
June 30, 2015 | 12.00M |
March 31, 2015 | 19.71M |
December 31, 2014 | 23.45M |
September 30, 2014 | 19.67M |
June 30, 2014 | 20.26M |
March 31, 2014 | 13.36M |
December 31, 2013 | 8.065M |
September 30, 2013 | 9.886M |
June 30, 2013 | 7.116M |
March 31, 2013 | 6.369M |
December 31, 2012 | 6.585M |
September 30, 2012 | 6.567M |
June 30, 2012 | 7.276M |
March 31, 2012 | 7.262M |
December 31, 2011 | 8.635M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
8.712M
Minimum
Sep 2020
14.38M
Maximum
Sep 2023
11.53M
Average
11.32M
Median
Dec 2021
SG&A Expense (TTM) Benchmarks
Actinium Pharmaceuticals Inc | 12.56M |
Bio-Path Holdings Inc | 4.339M |
Bristol-Myers Squibb Co | 8.377B |
NovaBay Pharmaceuticals Inc | 12.53M |
Palatin Technologies Inc | 13.34M |